Author Archives: Millie Nelson

Recipharm Indian plant to push global capacity to 1bn units

Recipharm will build a fill-finish facility in Uttarakhand, India increasing its fill-finish capacity to one billion sterile units per year. Contract development manufacturing organization (CDMO) Recipharm will construct the new facility on a greenfield site located near Dehradun in Uttarakhand as part of a joint project with Sobti. The Uttarakhand facility is the latest development in Recipharm’s partnership with Sobti, which began in November 2019 when the CDMO invested in Nichepharm. “This is part of our strategy to increase our…

CDMO Ardena invests $35m to expand three European sites

Ardena says the investment is driven by business growth, capacity needs and its ambition to become a leading mid-sized CDMO. In partnership with GHO Capital, contract development manufacturing organization (CDMO) Ardena has invested $35 million to expand its European operations in Belgium, Sweden, and the Netherlands to ensure the firm can offer end-to-end solutions. “All expansion work is expected to be complete by Q1 in 2023,” Gerjan Kemperman COO at Ardena told BioProcess Insider. The firm will expand its drug product…

Ins & Outs: Ex-Genentech employees plead guilty to sharing trade secrets with competitors

A former Genentech principal scientist and her husband face jail after pleading guilty to stealing corporate information and sharing it with fellow competitors. Meanwhile, JHL’s former CEO and COO plead not guilty. According to the suit, the story goes back to 2009 where Xanthe Lam and her husband, Allen Lam, conspired to commit stealing trade secret information from Genentech and passing the information to Taiwanese firm JHL Biotech (now Eden Biologics). The husband and wife duo stole confidential property, the…

SP doubles fill-finish capacity with Barcelona facility

SP has opened a large-scale facility in Barcelona, Spain doubling its global manufacturing capacity for fill-finish services. SP Scientific Products (SP) said that in order to meet the increasing demand for fill-finish and lyophilization (freeze dryer) equipment, it has more than doubled its global manufacturing capacity. The new 4,000 meter Barcelona plant will be equipped to offer fill-finish services and SP is also upping its production headcount and restructuring its manufacturing processes. “This is a multi-million-euro investment including the new…

Selexis and KBI to advance Immatics program towards IND

Selexis and KBI will provide integrated services to develop Immatics’ bispecific T cell engaging receptor program. Selexis will leverage its SUREtechnology to produce a clonal cell line for Immatics’ candidate IMA402 and KBI Biopharma will utilize its formulation, analytics, and manufacturing capabilities. No financial details have been disclosed. “Selexis and KBI are both JSR Life Sciences companies and are able offer partners integrated services that can accelerate biologic development timelines,” CEO of both companies Dirk Lange told BioProcess Insider. “These…

Recipharm: $500m fill-finish plant to help Africa gain ‘vaccine sovereignty’

Recipharm has signed a Memorandum of Understanding for the fill-finish of biotherapeutics and vaccines in Morocco.    Contract development manufacturing organization (CDMO) Recipharm signed the Memorandum of Understanding (MOU) with the King of Morocco, various Moroccan banks, and the Moroccan Government. As part of the MOU, approximately $500 million will be invested by the Moroccan government and others over the next five years to secure capacity and capability for the production of vaccines and biotherapeutics in Morocco. Recipharm will operate…

Batavia collaborates with Swiss start-up to deliver COVID-19 vaccine

Batavia Biosciences will use its HIP-Vax manufacturing technology to develop and deliver 1000 doses of RocketVax’s second generation COVID-19 vaccine candidate.   The deal, of which financial details have not been disclosed, sees Batavia develop the clinical process to deliver RocketVax’s (a subsidiary of Swiss Rockets AG) COVID-19 vaccine candidate RVX-13. RVX-13 does not use a single COVID-19 derived antigen but instead compromises all major immunogenic features of the COVID-19 virus. In turn, this aims to increase vaccine efficacy and…

Sartorius bolsters CGT portfolio with $118m stake in CellGenix

Sartorius has acquired a majority stake in CellGenix for $118 million, expanding its cell and gene therapy portfolio. Sartorius has acquired 51% of reagent manufacturing firm CellGenix for around $118 million in cash with plans to buy the remaining shares in 2023 and 2026. The firm anticipates that the acquisition will expand its cell and gene therapy portfolio through the addition of cytokines and media. “CellGenix has an excellent reputation on the market and brings in high technological expertise and…

Germany needs more biomanufacturing capacity, says Rentschler

Rentschler will expand production capacity at its Laupheim, Germany facility to support the increasing demand for complex antibodies. A report published by vfa bio and Boston Consulting Group assessing the state of biotech in Germany revealed the country is falling behind in production capacity when compared globally to others.  to other countries. “While companies in the US, South Korea, Ireland, and Switzerland have expanded their production facilities in the last three years, there has been no growth at all in…

Lonza invests $21m to expand China facility

Lonza says the expansion of its high potency API facility in Nansha, China will help support growing demand for ADC production. Swiss contract development manufacturing organization (CDMO) Lonza will add three 1,000 L GMP trains, including development laboratories with the capacity to produce small scale batches of highly potent APIs (HPAPIs). The expanded site will also boast six 1,000 L small molecule reactors, four 1,500L vessels, and isolation equipment adding capacity for a smooth transition between early-phase and large-scale commercial…